aTyr Pharma, a San Diego CA-based company that develops biologic therapeutics based on physiocrine, has raised $23m in Series C equity financing.
The round was led by Domain Associates, with participation from existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures.
The funds will be used to accelerate the development of aTyr’s preclinical pipeline and advance physiocrine drug candidates into clinical trials. Physiocrines are a recently elucidated class of endogenous human proteins that have the potential to address a wide range of diseases, including patient needs in blood, immune, and metabolism disorders.
The company was founded by Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and biotechnology entrepreneur, and John Clarke from Cardinal Partners.
In conjunction with the funding, Dr. James C. Blair will serve as a Director for aTyr Pharma, joining current board members Mr. John Clarke, Dr. David Mack, Dr. John Mendlein, Dr. Amir Nashat, Dr. Paul Schimmel and Dr. Jeff Watkins.